Imaging software developer Median Technologies has secured a deal to provide imaging services for a new phase II clinical trial sponsored by a leading pharmaceutical company.
The trial, which is for a highly aggressive cutaneous cancer type, is valued at $582,000 U.S. (422,000 euros) for Median, according to the vendor. Imaging data will be acquired from approximately 50 clinical sites worldwide, with an estimated start date in the second quarter of 2014.
Median said it will provide the whole set of imaging services, including independent central review (ICR) services, for the trial. Radiologists will perform ICR services using Median's Lesion Management Solutions (LMS) software, according to the company.